QTTB

Q32 Bio, Inc.'s stock (QTTB) has experienced significant volatility over the past six months, increasing by 66.80% over six months and 297.6% over the past year, but decreasing by 39.4% in the last month and 28.17% over the past month. In July 2026, positive 36-week topline results from Part B of the SIGNAL-AA clinical trial for bempikibart in alopecia areata led to a significant stock surge, including a +90.7% daily move. In August 2026, the company announced a follow-on cash raise of $187.6 million, reporting AA trial gains and a $200 million raise. In September 2026, Q32 Bio presented SIGNAL-AA clinical trial results at the European Academy of Dermatology and Venereology Congress 2026 and appointed Jos Trevejo as Chief Medical Officer and Ellie Hershberger as Chief Development Officer. In February 2026, Q32 Bio completed a registered direct offering of common stock and pre-funded warrants, generating approximately $10.5 million in gross proceeds.